GLP-1

#Cancer research #Clinical trial #Drug discovery #Francis Crick Institute #Funding #Genetic profiling #GLP-1 #Lung cancer #MHRA #National Institute for Health and Care Research #Obesity #Oncology #Rare disease #Regulatory #The Royal Marsden NHS Foundation Trust #University College London #Weight loss

DDW Highlights: 16 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, new research showed anti-IL-1β drugs could prevent lung cancer. Elsewhere, the… Read More

#Podcasts

#Cancer research #Clinical trial #Drug discovery #Funding #Genetic profiling #GLP-1 #Lung cancer #MHRA #National Institute for Health and Care Research #Obesity #Oncology #Rare disease #Regulatory #The Francis Crick Institute #The Royal Marsden NHS Foundation Trust #University College London #Weight loss

This week in Drug Discovery (8 – 12 June) 

News round-up for 8 – 12 June by Bruno Quinney, Content Team at DDW.  This week, new research suggests anti-IL-1β drugs could prevent lung cancer. Elsewhere, the UK is set to benefit from specialised blood tests and funding for researchers.   The top stories:   … Read More

#News

#GLP-1 #Obesity #Weight loss

Obesity therapies could offer benefits beyond weight loss 

MetaVia has presented data showing its obesity therapies could offer broader benefits than weight loss alone.  DA-1726, a novel dual agonist targeting glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), reduced body weight by 9.1% at Day 54 in a Phase I trial, as well as reducing waist… Read More

#News

#Boehringer Ingelheim #GLP-1 #Obesity #Weight loss

GLP-1 reduces liver fat by 63%, trial results show 

The glucagon/GLP-1 dual agonist survodutide could reduce liver fat by 63%, results show.  Boehringer Ingelheim reported positive results from two Phase III trials, which demonstrated patients lost 63% liver fat, 34% visceral fat and showed minimal lean mass change at the highest dose.  The results demonstrate survodutide’s potential to… Read More

#News

#Eli Lilly #GLP-1 #Obesity #Phase III trial #Weight loss

Lilly’s new triple agonist delivers weight loss equal to bariatric surgery

Eli Lilly has announced positive topline results from TRIUMPH-1, a Phase III clinical trial evaluating the efficacy and safety of retatrutide, a GIP, GLP-1,and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes.   At 80 weeks,… Read More

#News

#GLP-1 #Mounjaro #Obesity #Ozempic #Weight loss

Weight-loss drugs’ challenge to pharma’s safety infrastructure

For the huge commercial success represented by GLP-1 agonists such as Mounjaro and Ozempic, particularly now in the context of treating obesity, they also present an operational nightmare for companies. That's as  volumes of adverse events threaten to swamp existing safety workflows. Qinecsa’s Daniel O’Keeffe assesses the scale of the problem.  The success of Glucagon-Like Peptide-1 (GLP-1) receptor agonists as modern weight-loss solutions has yet to… Read More

#Exclusive Content #Opinion

#AI #Autoimmune disease #Breast cancer #Clinical trial #Cystic fibrosis #Diabetes #FDA #Fractyl Health #Gene therapy #GLP-1 #Institute of Cancer Research #Oncology #Phesi

This week in Drug Discovery (18 – 22 May)

News round-up for 18 – 22 May by Bruno Quinney, Content Team at DDW.    This week, a report showed patients in Europe face barriers to patient access. Elsewhere, Wellcome prizes are facilitating research in both tropical disease and mental health.    The… Read More

#News

#AI #Autoimmune disease #Breast cancer #Clinical trial #Cystic fibrosis #Diabetes #FDA #Fractyl Health #Gene therapy #GLP-1 #Institute of Cancer Research #Oncology #Phesi

DDW Highlights: 19 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research uncovered new treatment pathways for hard to treat breast cancers. Elsewhere,… Read More

#Podcasts

#AI #Autoimmune disease #Breast cancer #Clinical trial #Cystic fibrosis #Diabetes #FDA #Fractyl Health #Gene therapy #GLP-1 #Institute of Cancer Research #Oncology #Phesi

This week in Drug Discovery (11 – 15 May) 

News round-up for 11 – 15 May by Bruno Quinney, Content Team at DDW.  This week, research has uncovered new treatment pathways for hard to treat breast cancers. Elsewhere, therapies given the green light could combat type 2 diabetes and generalised myasthenia gravis.  The top stories:   … Read More

#News

Cell and gene therapies
#Diabetes #Fractyl Health #Gene therapy #GLP-1 #Phase I trial

First GLP-1 gene therapy gets green light for diabetes trial

Fractyl Health has received Clinical Trial Application authorisation in the Netherlands to initiate the Phase I/II first-in-human study of RJVA-001, the first clinical candidate from the company’s Rejuva Smart GLP-1 gene therapy platform.   With this authorisation, Fractyl believes RJVA-001 is the first adeno-associated virus (AAV)-based gene therapy… Read More

#News #Trending News

#Drug discovery #GLP-1 #MetaVia #Obesity

What will define the winners in a crowded GLP-1 era? 

HH Kim, CEO and President of MetaVia, asks what the next generation of GLP-1 drugs might look like.  Over the past two decades, only a few biotech sectors have experienced a hype cycle as rapid and publicly frenzied as the obesity drug sector. In just over a year, GLP-1s have transformed from a… Read More

#Exclusive Content

#Antibody drug conjugate (ADC) #Cytokine Release Syndrome (CRS) #Diabetes #Eli Lilly #GLP-1 #Idiopathic pulmonary fibrosis #Lung disease #Mergers and acquisitions #MHRA #Obesity #Poolbeg Pharma #Respiratory #Weight loss

DDW Highlights: 28 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, an obesity drug proved it could improve liver health independent of weight… Read More

#Podcasts

Boy tests his blood sugar levels at home
#GLP-1 #Novo Nordisk #Paediatrics #Phase III trial #Type 2 diabetes

Semaglutide could be first oral GLP-1 RA therapy for children

Positive topline results from Novo Nordisk’s PIONEER TEENS, a Phase IIIa trial evaluating oral semaglutide for type 2 diabetes demonstrated a superior reduction in HbA1c (a measure of blood sugar control) over placebo.  The trial, in children and adolescents aged 10–17 years with type 2 diabetes, also… Read More

#News

#Antibody drug conjugate (ADC) #Cytokine Release Syndrome (CRS) #Diabetes #Eli Lilly #GLP-1 #Idiopathic pulmonary fibrosis #Lung disease #Mergers and acquisitions #MHRA #Obesity #Poolbeg Pharma #Respiratory #Weight loss

This week in Drug Discovery (20 – 24 April) 

News round-up for 20 – 24 April by Bruno Quinney, Content Team at DDW.  This week, an obesity drug could improve liver health independent of weight loss. Elsewhere, Lilly is back in the news for both its type 2 diabetes drug and the company’s latest acquisition.  The top stories:   … Read More

#News

Human liver
#Diabetes #GLP-1 #Obesity #Weight loss

GLP-1 improves liver health independent of weight loss

Researchers at Sinai Health have found that semaglutide acts directly on a subset of liver cells to improve organ function, and does so independently of weight loss.   The finding challenges long-held assumptions about how GLP-1 medicines work in the liver and could reshape how physicians treat metabolic… Read More

#Editor's Choice #News